| Cohort Name |
A Feasibility Study for Deep and Frequent Phenotyping for Experimental Medicine in Dementia |
| Cohort Acronym |
DFP Pilot study |
| Study Overview |
This is a multi-centre, non-interventional study in subjects with early clinical AD. This feasibility study aims to identify markers of change in early AD using clinical assessment, cognitive assessment, gait and ophthalmological assessments, molecular markers in cerebrospinal fluid (CSF), blood and urine, Positron Emission Tomography (PET) imaging, Magnetic Resonance Imaging (MRI), Magnetoencephalography (MEG) and Electroencephalography (EEG). Participant acceptability, operational practicability and governance, ethics and agreements necessary for a full trial will be assessed. |
| #Subjects at Baseline |
24 |
| Institution Name |
Kings College London |
| Department Name |
|
| City |
London |
| Study/Database Website |
|
| Principal Investigator (PI) |
Simon Lovestone/Vanessa Raymont |
| Key Study References |
Koychev I, Lawson J, Chessell T, et alDeep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer’s diseaseBMJ Open 2019;9:e024498. doi: 10.1136/bmjopen-2018-024498 |
| Population Based Study? |
yes |
| Family Based Study? |
no |
| Clinical based sample? |
yes |
| Is there follow-up data available? |
yes |
| Were participants included prior to development of dementia (may refer to controls only)? |
no |
| Were participants included prior to development of MCI (may refer to controls only)? |
no |
| How is data collected? |
|
| Who carries out data collection? |
|
| Does this take place in participants' homes or at a central location? |
six sites across the UK |
| Do participants take part individually or are families/partners involved? |
yes |
| Dementia cases ascertained as part of study: |
yes |
| How many times followed up? |
5 |
| Study start date |
15/12/2014 00:00:00 |
| Study end date |
18/01/2016 00:00:00 |
| Is study ongoing? |
no |
| Is study still recruiting? |
no |
| Inclusion criteria |
1. Men and women aged 50 to 85 years, inclusive, at baseline on Day 1. |